|
Patent landscape, scope, and claims: |
United States Patent 5,034,394: Scope, Claims, and US Patent Landscape
What does US 5,034,394 claim?
US Patent 5,034,394 is directed to topical ophthalmic delivery using a controlled-release system containing a glucocorticoid (corticosteroid) formulated for ocular administration. The patent’s claim scope centers on (1) the drug identity/class, (2) the ocular route, and (3) the formulation architecture that controls release at the ocular surface and/or within peri-ocular tissues.
Core subject matter (high-level):
- Indication/route: ocular administration (eye/tissue around the eye)
- Active: glucocorticoid (steroid) for treatment of ocular inflammatory conditions
- Delivery system: a formulation designed to control release rather than immediate release
How broad is the claim scope? (Claim structure indicators)
The claim set is organized around composition and use concepts rather than device mechanics alone. Scope typically expands along three axes:
-
Active breadth
- The active set is framed around glucocorticoids rather than a single compound only.
- Claim language in this family style typically captures multiple members of a steroid class if they fall within the defined glucocorticoid category.
-
Formulation breadth
- Claim scope is anchored to the controlled-release system defining the delivery behavior.
- Patents of this type often cover both:
- the composition (active + carrier/matrix/system components), and
- the pharmaceutical formulation configured for ocular use.
-
Route/setting breadth
- Claims focus on ocular administration, which limits infringement to products used for eye treatment rather than systemic or non-ocular uses.
- When the claims are written with less restrictive language (for example, “ophthalmic” or “ocular”), infringement exposure can extend beyond a single named eye-drop format into broader ocular delivery forms.
What are the key claim limitations that control infringement risk?
For patents of this type, enforcement hinges on whether an accused product matches the claim’s required combination of:
- a glucocorticoid active, and
- a controlled-release ocular formulation, and
- ocular administration (not systemic dosing).
The most important limitation is usually the delivery system requirement. If a competitor’s product is immediate-release or uses a fundamentally different release-control architecture, it can fall outside claim elements even if it uses the same glucocorticoid.
Claim coverage map (practical reading)
Below is a pragmatic claim-landscape map aligned to how 5,034,394-style claims are generally drafted and litigated in the ophthalmic controlled-release space.
| Scope dimension |
What matters for coverage |
Typical “in or out” triggers |
| Active drug |
Covered glucocorticoid identity/class |
“In” if the active qualifies as a glucocorticoid as claimed; “out” if the active is non-steroidal or a steroid not within the claim’s definition |
| Route |
Ocular administration |
“In” if the product is formulated/used for eye treatment; “out” if the same formulation is used for non-ocular indications |
| Delivery system |
Controlled-release mechanism and formulation system |
“In” if release is controlled by the claimed system components/structure; “out” if release is immediate or controlled by a different, non-equivalent system |
How does 5,034,394 fit into the broader US ophthalmic steroid patent landscape?
Where is the prior art pressure highest?
The highest prior-art pressure for this kind of patent typically comes from:
- earlier ophthalmic steroid formulations (including suspensions, solutions, and earlier controlled-release approaches),
- controlled-release ocular systems (polymers, depots, inserts, microstructures, nanoparticles depending on era), and
- formulation-driven patents that claim carriers and ocular performance.
In the US, prior art pressure increases where the earlier patents already describe:
- the steroid class for eye inflammation, and
- a controlled-release ocular system using common excipient families.
How do competitors usually design around this type of claim?
Common design-around strategies in this segment include:
- switching from controlled-release to immediate-release steroid delivery (or vice versa),
- using a steroid but changing the controlled-release system architecture so it does not meet claim-required structural elements,
- shifting the formulation into a different claim category (for example, a different delivery form if the claims are tightly drafted to a specific ocular formulation class).
What does the expiration timeline imply for filing strategy?
US patents that issued in the early-to-mid 1990s generally face:
- near-term expiry of baseline composition claims, but
- continuation-related activity earlier or around filing windows.
For business planning, the practical effect is that value shifts from “blocking” composition claims toward:
- later-generation improvements (new actives, new release systems, new targeting, new combination regimens),
- regulatory exclusivity and formulary position, and
- enforcing later patents with narrower, more modern claim sets.
US patent landscape: what other patent themes cluster around this space?
Cluster 1: Ophthalmic glucocorticoid formulations
This cluster covers patents directed to:
- steroid choice, salt forms, and blends;
- ocular tolerability and stability;
- ocular dosing regimens and preservative systems.
Relationship to 5,034,394: these patents can overlap on the active and ocular route but not on controlled-release formulation elements.
Cluster 2: Controlled-release ocular delivery systems
This cluster covers:
- polymeric matrices,
- depots and inserts,
- micro/nanostructured delivery systems,
- permeability modifiers and release-rate control approaches.
Relationship to 5,034,394: these patents overlap on the delivery system concept. Overlap can create both:
- cross-licensing opportunities, and
- freedom-to-operate (FTO) complexity for products aiming at controlled release with steroids.
Cluster 3: Steroid plus combination therapy
Later landscape often includes combination patents, for example:
- steroid + antiinfective,
- steroid + NSAID,
- steroid + glaucoma drug.
Relationship to 5,034,394: many combination patents avoid earlier controlled-release constraints by adding new actives and claim elements.
Freedom-to-operate implications for a hypothetical product built on this concept
To assess infringement exposure for a product conceptually aligned with 5,034,394, the critical FTO gates are:
- Does the product include a glucocorticoid active that falls within the claim definition?
- Is the ocular formulation truly controlled-release as defined by the patent’s claimed delivery system elements?
- Is the use or labeling ocular-based?
- Do any later patents in the same family or citing set introduce narrower, more specific embodiments that would still be enforceable?
What to expect in claim breadth and enforcement posture
Patents in this category tend to have enforcement posture driven by:
- claim element matching (especially controlled-release system structure),
- product performance proof in litigation (release characteristics),
- and validity challenges tied to prior art ocular steroid formulations and controlled-release systems.
This means that “steroid + eye” alone rarely drives infringement. The delivery system element tends to be the decisive gate.
Key Takeaways
- US 5,034,394 is a US ophthalmic controlled-release glucocorticoid patent, with claim scope built around steroid identity/class + ocular route + controlled-release formulation architecture.
- Infringement exposure is driven primarily by whether an accused product meets the controlled-release system elements, not just whether it uses a steroid in the eye.
- The competitive landscape clusters into three main buckets: (1) ophthalmic steroid formulations, (2) controlled-release ocular systems, and (3) later combination regimens.
- US value for this issuance-era patent typically shifts over time from broad blocking power to later-generation improvements and new claim sets.
FAQs
-
Is US 5,034,394 limited to one specific steroid?
The claim set is directed to glucocorticoid steroids rather than only one single steroid compound, which can broaden coverage depending on exact claim wording.
-
Does using a steroid in an eye drop infringe automatically?
No. The patent scope hinges on the controlled-release formulation system and the ocular administration context, not just steroid presence.
-
What is the main design-around lever?
The most common design-around is changing the release-control architecture so the formulation does not meet the delivery system elements required by the claims.
-
How does prior art affect this patent’s practical enforceability?
Prior art typically pressures validity where earlier patents already disclose steroid ocular formulations and controlled-release ocular delivery in overlapping ways.
-
What tends to matter most for a competitor’s FTO?
The FTO focuses on element-by-element comparison of: (a) steroid/class, (b) ocular route, and (c) controlled-release system features, plus any later, narrower patents in the same technological neighborhood.
References
[1] United States Patent and Trademark Office. US Patent 5,034,394. (Record for title, bibliographic data, and claims).
More… ↓
⤷ Start Trial
|
